

10/143625

FORM PTO-1449/A and B (Modified)		APPLICATION NO. [REDACTED]	ATTY. DOCKET NO.: C1039/70073US00
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		FILING DATE: Herewith <u>12/22/03</u>	
		APPLICANT: Krieg et al.	
		GROUP ART UNIT: <u>1645</u>	EXAMINER: <u>MANNIFIELD</u>
Sheet 1 of 6			

## U.S. PATENT DOCUMENTS

Examiner's Initials#	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
	*	3,906,092		Hilleman et al.	09-16-1975
	*	5,023,243		Tullis	06-11-1991
	*	5,248,670		Draper et al.	09-28-1993
	*	5,585,479		Hoke et al.	12-17-1996
	*	5,663,153		Hutcherson et al.	09-02-1997
	*	5,723,335		Hutcherson et al.	03-03-1998
	*	5,786,189		Locht et al.	07-28-1998
	*	5,849,719		Carson et al.	12-15-1998
	**	6,194,388	B1	Krieg et al.	02-27-2001
	**	6,207,646	B1	Krieg et al.	03-27-2001
	**	6,214,806	B1	Krieg et al.	04-10-2001
	**	6,218,371	B1	Krieg et al.	04-17-2001
	**	6,239,116	B1	Krieg et al.	05-29-2001
	**	6,339,068	B1	Davis et al.	01-15-2002

## FOREIGN PATENT DOCUMENTS

Examiner's Initials#	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/Country	Number	Kind Code			
	*	EP	0468520	A3		01-29-1992	
	*	EP	0302758	B1		11-08-1989	
	*	WO	91/12811			09-05-1991	
	*	WO	92/03456			04-05-1992	
	*	WO	92/18522			10-29-1992	
	*	WO	92/21353			12-10-1992	
	*	WO	94/19945			09-15-1994	
	*	WO	95/05853			03-02-1995	
	*	WO	95/26204			10-05-1995	
	*	WO	96/02555	A1		02-01-1996	
	*	WO	96/35782			11-14-1996	
	*	WO	97/28259			08-07-1997	
	*	WO	98/14210			04-09-1998	

## OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials#	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
	*	ADYA N et al., Expansion of CREB's DNA recognition specificity by Tax results from interaction with Ala-Ala-Arg at positions 282-284 near the conserved DNA-binding domain of CREB. <i>Proc Natl Acad Sci USA</i> 91(12):5642-6, Jun. 7, 1994.	
	*	ACRAHAWA, Molecular Med Today, Vol 6, pp. 72-81 (2000)	
	*	ANGIER N, Microbe DNA seen as alien by immune system, <i>New York Times</i> , Apr. 11, 1995.	
	*	AZAD RF et al., Antiviral activity of a phosphorothioate oligonucleotide complementary to RNA of the human cytomegalovirus major immediate-early region, <i>Antimicrobial Agents and Chemotherapy</i> , 37:1945-1954, Sep. 1993.	

741376.1

NM Manfield 6-26-05

10/74 3625

FORM PTO-1449/A and B (Modified)		APPLICATION NO. [REDACTED]	ATTY. DOCKET NO.: C1039/70073US00
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		FILING DATE: Herewith	
		APPLICANT: Krieg et al.	
Sheet 2 of 6		GROUP ART UNIT [REDACTED] 1045	EXAMINER: [REDACTED] MINNIEFIELD

*	AZUMA, Biochemical and immunological studies on cellular components of tubercle bacilli. <i>Kekkaku</i> , 69(9):45-55 (1992).	
*	BALLAS ZK et al., Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. <i>J Immunol</i> 157(5):1840-5 (1996).	
*	BAYEVER E, systemic administration of a phosphorothioate oligonucleotide with a sequence complementary to p53 for acute myelogenous leukemia and myelodysplastic syndrome: initial results of a Phase I trial, <i>Antisense Res Dev</i> , 3:383-390 (1993).	
*	BENNETT RM et al., DNA binding to human leukocytes. Evidence for a receptor-mediated association, internalization, and degradation of DNA. <i>J Clin Invest</i> 76(6):2182-90 (1985).	
*	BIOLABS 1988-1989 Catalog, Random Primer #s 1230, 1601, 1602.	
*	BLAXTER et al., Genes expressed in Brugia malayi infective third stage larvae, <i>Mol Biochem Parasitol</i> , 77:77-93 (Apr. 1996).	
*	BOGGS RT et al., Characterization and modulation of immune stimulation by modified oligonucleotides. <i>Antisense Nucleic Acid Drug Dev</i> 7(5):461-71, Oct. 1997.	
*	BRANDA et al., Immune stimulation by an antisense oligomer complementary to the rev gene of HIV-1, <i>Biochem Pharmacol</i> , 45(10):2037-2043 (1993).	
*	BRANDA RF et al., Amplification of antibody production by phosphorothioate oligodeoxynucleotides. <i>J Lab Clin Med</i> 128(3):329-38, Sep. 1996.	
*	BRISKIN M et al., Lipopolysaccharide-unresponsive mutant pre-B-cell lines blocked in NF-kappa B activation, <i>Mol Cell Biol</i> , 10:1:422-5 (1990).	
*	CHACE J et al., Regulation of differentiation in CD5+ and conventional B cells, <i>Clin Immunol Immunopathol</i> , 68(3):327-332 (1993).	
*	CHANG YN et al., The palindromic series I repeats in the simian cytomegalovirus major immediate-early promoter behave as both strong basal enhancers and cyclic AMP response elements. <i>J Virol</i> 64(1):264-77, Jan. 1990.	
*	CHU RS et al., CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. <i>J Exp Med</i> 186(10):1623-31, Nov. 17, 1997.	
*	COWDERY J et al., Bacterial DNA induces NK cells to produce IFN-gamma in vivo and increases the toxicity of lipopolysaccharides, <i>J Immunol</i> , 156:12:4570-5 (1996).	
*	CROSBY SD et al., The early responses gene NGFI-C encodes a zinc finger transcriptional activator and is a member of the GCGGGGGCG (GSG) element-binding protein family, <i>Mol Cell Biol</i> , 2:3835-3841 (1991).	
*	CRYSTAL R, Transfer of genes to humans: early lessons and obstacles to success, <i>Science</i> , 270:404-410 (1995).	
*	ENGLISCH et al., Chemically modified oligonucleotides as probes and inhibitors, <i>Angew Chem Int Ed Engl</i> , 30:613-629 (1991).	
*	ERB KJ et al., Infection of mice with Mycobacterium bovis-bacillus Calmette-Guerin (BCG) suppresses allergen-induced airway eosinophilia. <i>J Exp Med</i> 187(4):561-9, Feb. 16, 1998.	
*	ETLINJER, Carrier sequence selection--one key to successful vaccines, <i>Immunology Today</i> , 13(2):52-55 (1992).	
*	European Patent Office, International Search Authority--Search Report, PCTUS95/01570, Jul. 11, 1995.	
*	FOX RI, Mechanism of action of hydroxychloroquine as an antirheumatic drug, <i>Chem Abstracts</i> 120:15, Abstract No. 182630 (Apr. 29, 1994).	
*	GURA T, Antisense has growing pains, <i>Science</i> , 270:575-576 (1995).	
*	HADDEN J et al., Immunopharmacology, <i>JAMA</i> , 268:20:2964-2969 (1992).	
*	HADDEN J et al., Immunostimulants, <i>TIPS</i> , 141:169-174 (1993).	
*	HALPERN MD et al., Bacterial DNA induces murine interferon-gamma production by stimulation of interleukin-12 and tumor necrosis factor-alpha. <i>Cell Immunol</i> 167(1):72-8 (1996).	

10/743625

FORM PTO-1449/A and B (Modified)		APPLICATION NO.: [REDACTED]	ATTY. DOCKET NO.: C1039/70073US00
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		FILING DATE: Herewith	
		APPLICANT: Krieg et al.	
Sheet	3	of	6
		GROUP ART UNIT: [REDACTED] 1645	EXAMINER: [REDACTED] MINNIFIELD

*	HATZFELD J, Release of early human hematopoietic progenitors from quiescence by antisense transforming growth factor $\beta$ 1 or Rb oligonucleotides, <i>J Exp Med</i> , 174:925-929 (1991).		
*	HIGHFIELD PE, Sepsis: the more, the murkier, <i>Biotechnology</i> , 12:828, Aug. 12, 1994.		
*	HOEFFLER JP et al., Identification of multiple nuclear factors that interact with cyclic adenosine 3',5'-monophosphate response element-binding protein and activating transcription factor-2 by protein-protein interactions. <i>Mol Endocrinol</i> 5(2):256-66, Feb. 1991.		
*	IGUCHI-ARIGA SM et al., CpG methylation of the cAMP-responsive enhancer/promoter sequence TGACGTCA abolishes specific factor binding as well as transcriptional activation. <i>Genes Dev</i> 3(5):612-9, May 1989.		
*	ISHIKAWA R et al., IFN induction and associated changes in splenic leukocyte distribution. <i>J Immunol</i> 150(9):3713-27, May 1, 1993.		
*	IVERSEN P et al., Pharmacokinetics of an antisense phosphorothioate oligodeoxynucleotide against rev from human immunodeficiency virus type 1 in the adult male rat following single injections and continuous infusion, <i>Antisense Res Dev</i> , 4:43-52 (1994).		
*	JAKWAY J et al., Growth regulation of the B lymphoma cell line WEHI-231 by anti-immunoglobulin, lipopolysaccharide, and other bacterial products, <i>J Immunol</i> , 137:7:2225-31 (1996).		
*	JAROSZEWSKI J et al., Cellular uptake of antisense oligonucleotides, <i>Adv Drug Delivery Rev</i> , 6:3:235-50 (1991).		
*	KATAOKA T et al., Antitumor activity of synthetic oligonucleotides with sequences from cDNA encoding proteins of <i>Mycobacterium bovis</i> BCG, <i>Jpn J Cancer Re.</i> , 83:244-247, Mar. 1992.		
*	KIMURA Y et al., Binding of oligoguanylate to scavenger receptors is required for oligonucleotides to augment NK cell activity and induce IFN, <i>J Biochem</i> , 116(5):991-994 (1994).		
*	KLINE JN et al., CpG motif oligonucleotides are effective in prevention of eosinophilic inflammation in a murine model of asthma. <i>J Invest Med</i> 44(7):380A (1996).		
*	KLINE JN et al., CpG oligonucleotides can reverse as well as prevent TH2-mediated inflammation in a murine model of asthma. <i>J Invest Med</i> 45(7):298A (1997).		
*	KLINE JN et al., Immune redirection by CpG oligonucleotides. Conversion of a Th2 response to a Th1 response in a murine model of asthma. <i>J Invest Med</i> 45(3):282A (1997).		
*	KLINMAN DM et al., CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. <i>Proc Natl Acad Sci USA</i> 93(7):2879-83 (1996).		
*	KRIEG AM et al., Phosphorothioate oligodeoxynucleotides: antisense or anti-protein?, <i>Antisense Res Dev</i> , 5:241 (1995).		
*	KRIEG AM et al., The role of CpG dinucleotides in DNA vaccines, <i>Trends in Microbiology</i> , 6:23-27, Jan. 1998.		
*	KRIEG AM et al., A role for endogenous retroviral sequences in the regulation of lymphocyte activation, <i>J Immunol</i> 143(8):2448-51, Oct. 15, 1989.		
*	KRIEG AM et al., CpG DNA: A pathogenic factor in systemic lupus erythematosus? <i>J Clin Immunol</i> , 15(6):284-292 (1995).		
*	KRIEG AM et al., CpG motifs in bacterial DNA trigger direct B-cell activation. <i>Nature</i> 374:546-9, 6 Apr. 1995.		
*	KRIEG AM et al., Leukocyte stimulation by oligodeoxynucleotides, <i>Applied Antisense Oligonucleotide Technology</i> 431-448 (1998).		
*	KRIEG AM et al., Modification of antisense phosphodiester oligodeoxynucleotides by a 5' cholesteryl moiety increases cellular association and improves efficacy, <i>Proc Natl Acad Sci USA</i> , 90:1048-1052 (1993).		
*	KRIEG AM et al., Oligodeoxynucleotide modifications determine the magnitude of B cell stimulation by CpG motifs. <i>Antisense Nucleic Acid Drug Dev</i> 6(2):133-9, Summer 1996.		

10/743625

FORM PTO-1449/A and B (Modified)		APPLICATION NO.: [REDACTED]	ATTY. DOCKET NO.: CI039/70073US00
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		FILING DATE: Herewith	
		APPLICANT: Krieg et al.	
Sheet 1 of 6		GROUP ART UNIT: [REDACTED] 1642	EXAMINER: [REDACTED] MINNIEFIELD

*	KRIEG AM et al., Uptake of oligodeoxyribonucleotides by lymphoid cells is heterogeneous and inducible. <i>Antisense Res Dev</i> 1(2):161-71, Summer 1991.	
C1	KRIEG et al., Immunology Today, Vol. 21, No. 10, pp. 521-526 (2000)	
*	KURAMOTO et al., Oligonucleotide sequences required for natural killer cell activation, <i>Jpn J Cancer Res.</i> 83:1128-1131, Nov. 1992.	
*	LEONARD GA et al., Conformation of guanine 8-oxoadenine base pairs in the crystal structure of d(CGCGAATT(O8A)GCG), <i>Biochemistry</i> , 31(36):8415-8420 (1992).	
*	LIPFORD G et al., CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: a new class of vaccine adjuvants, <i>Eur J Immunol</i> , 27(9):2340-4 (1997).	
D U P L I C A T E	LIPFORD G et al., Immunostimulatory DNA: sequence-dependent production of potentially harmful or useful cytokines, <i>Eur J Immunol</i> , 12(27):3420-3426 (1997)	
*	MACFARLANE DE et al., Antagonism of immunostimulatory CpG-oligodeoxynucleotides by quinacrine, chloroquine, and structurally related compounds. <i>J Immunol</i> 160(3):1122-31, Feb. 1, 1998.	
*	MASTRANGELO MJ et al., Gene therapy for human cancer: an essay for clinicians. <i>Seminars Oncology</i> , 23(1):4-21 (1996).	
*	MATSON S et al., Nonspecific suppression of [ <sup>3</sup> H]thymidine incorporation by control oligonucleotides. <i>Antisense Res Dev</i> 2(4):325-30, Winter 1992.	
C2	MOJCIKUSKE et al., Molecular Med. Vol. 5, No. 5, pp 287-300 (1999)	
*	MCINTYRE K et al., A sense phosphorothioate oligonucleotide directed to the initiation codon of transcription factor NF-kappa B p65 causes sequence-specific immune stimulation, <i>Antisense Res Dev</i> , 3(4):309-322 (1993).	
*	MESSINA et al., Stimulation of in vitro murine lymphocyte proliferation by bacterial DNA, <i>J Immunol</i> , 147(6):1759-1764, Sep. 15, 1991.	
*	MESSINA, et al., The influence of DNA structure on the in vitro stimulation of murine lymphocytes by natural and synthetic polynucleotide antigens, <i>Cell Immunol</i> , 147:148-157 (1993).	
*	MOJCIK C et al., Administration of a phosphorothioate oligonucleotide antisense murine endogenous retroviral MCF env causes immune effect in vivo in a sequence-specific manner, <i>Clin Immunol Immunopathol</i> , 67(2):130-136 (1993).	
*	MOTTRAM et al., A novel CDC2-related protein kinase from leishmania mexicana, LmmCRK1, is post-translationally regulated during the life cycle, <i>J Biol Chem</i> , 268:28 21044-21052 (Oct. 1993).	
*	NYCE J et al., DNA antisense therapy for asthma in an animal model, <i>Nature</i> , 385:721-5 (1997).	
*	PISETSKY D, Stimulation of in vitro proliferation of murine lymphocytes by synthetic oligodeoxynucleotides, <i>Molecular Biology Reports</i> , 18:217-221 (1993).	
*	PISETSKY DS et al., Stimulation of murine lymphocyte proliferation by a phosphorothioate oligonucleotide with antisense activity for herpes simplex virus. <i>Life Science</i> , 54:101-107 (1994).	
*	PISETSKY DS, Immunological consequences of nucleic acid therapy, <i>Antisense Res Dev</i> , 5:219-225 (1995).	
*	PISETSKY DS, The immunological properties of DNA, <i>J Immunol</i> , 156:421-423 (1996).	
*	QUDDUS J et al., Treating activated CD4+ T cells with either of two distinct DNA methyltransferase inhibitors, 5-azacytidine or procainamide, is sufficient to cause a lupus-like disease in syngeneic mice. <i>J Clin Invest</i> 92(1):38-53, Jul. 1993.	
*	RAZ E et al., Intradermal gene immunization: the possible role of DNA uptake in the induction of cellular immunity to viruses, <i>Proc Natl Acad Sci USA</i> , 91:9519-9523 (1994).	
*	ROJANASAKUL Y, Antisense oligonucleotide therapeutics: drug delivery and targeting. <i>Advanced Drug Delivery Reviews</i> , 18:115-131 (1996).	
*	ROMAN M et al., Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. <i>Nat Med</i> 3(8):849-854, Aug. 1997.	

10/743625

FORM PTO-1449/A and B (Modified)		APPLICATION NO.: [REDACTED]	ATTY. DOCKET NO.: C1039/70073US00
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		FILING DATE: Herewith	
		APPLICANT: Krieg et al.	
Sheet	5	of 6	GROUP ART UNIT: 1645 EXAMINER: MINNIE TIELED

*	SATO et al., Immunostimulatory DNA sequences necessary for effective intradermal gene immunization, <i>Science</i> , 273:352-354 (1996).	
*	SCHNELL N et al., Identification and characterization of a <i>Saccharomyces cerevisiae</i> gene (PAR1) conferring resistance to iron chelators, <i>Eur J Biochem</i> , 200:487-493 (1991).	
*	SCHWARTZ DA et al., CpG motifs in bacterial DNA cause inflammation in the lower respiratory tract. <i>J Clin Invest</i> 100(1):68-73, Jul. 1, 1997.	
*	SHIRAKAWA T et al., The inverse association between tuberculin responses and atopic disorder. <i>Science</i> 275(5296):77-9, Jan. 3, 1997.	
*	SPARWASSER T et al., Macrophages sense pathogens via DNA motifs: induction of tumor necrosis factor-alpha-mediated shock. <i>Eur J Immunol</i> 27(7):1671-9, Jul. 1997.	
*	STEIN CA et al., Oligodeoxynucleotides as inhibitors of gene expression: a review, <i>Cancer Res</i> , 48:2659-2668 (1988).	
*	STULL RA et al., Antigene, ribozyme, and aptamer nucleic acid drugs: progress and prospects, <i>Pharm Res</i> , 12(4):465-483 (1995).	
*	SUBRAMANIAN et al., Theoretical considerations on the 'spine of hydration' in the minor groove of d(CCGGAATTCGCG) d(CGGCTTAAGCGC): Monte Carlo computer simulation, <i>Proc Natl Acad Sci USA</i> , 85:1836-1840, Mar. 1988.	
*	TANAKA T et al., An antisense oligonucleotide complementary to a sequence in I gamma 2b increases gamma 2b germline transcripts stimulates B cell DNA synthesis and inhibits immunoglobulin secretion, <i>J Exp Med</i> , 175: 597-607 (1992).	
*	The New England Biolabs Catalog, 1988-1989, item #1230.	
*	TOKUNAGA T et al., A synthetic single-stranded DNA, poly (dG, dC), induces interferon- $\alpha/\beta$ and - $\gamma$ , augments natural killer activity and suppresses tumor growth, <i>Jpn J Cancer Res</i> , 79:682-686, Jun. 1988.	
*	TOKUNAGA T et al., synthetic oligonucleotides with particular base sequences from the cDNA encoding proteins of <i>Mycobacterium bovis</i> BCG induce interferons and activate natural killer cells, <i>Microbiol Immunol</i> , 36(1):55-66 (1992).	
*	UHLMANN, et al., Antisense oligonucleotides: a new therapeutic principle, <i>Chem Rev</i> , 90:543-584 (1990).	
*	WAGNER RW, Gene inhibition using antisense oligodeoxynucleotides, <i>Nature</i> , 372:333-335 (1994).	
*	WALLACE et al., Oligonucleotide probes for the screening of recombinant DNA libraries, <i>Methods Enzymol</i> , 152:432-442 (1987).	
C4	WEINER, G.J. of Leukocyte Biology, Vol. 68, pp. 455-463 (2000)	
*	WEISS R, Upping the antisense ante: scientists bet on profits from reverse genetics, <i>Science</i> , 139:108-109 (1991).	
*	WHALEN RG, DNA vaccines for emerging infection diseases: what if?, <i>Emerg Infect Dis</i> , 2(3):168-175 (1996).	
*	WU GY et al., Receptor-mediated gene delivery and expression in vivo, <i>J Biol Chem</i> , 263:14621-14624 (1988).	
*	WU-PONG S, Oligonucleotides: opportunities for drug therapy and research, <i>Pharmaceutical Technology</i> , 18:102-114 (1994).	
*	YAMAMOTO S et al., DNA from bacteria, but not from vertebrates, induces interferons, activates natural killer cells, and inhibits tumor growth, <i>Microbiol Immunol</i> , 36(9):983-997 (1992).	
*	YAMAMOTO S et al., In vitro augmentation of natural killer cell activity and production of interferon-alpha/beta and -gamma with deoxyribonucleic acid fraction from <i>Mycobacterium bovis</i> BCG. <i>Jpn J Cancer Res</i> 79:866-73, Jul. 1988.	
*	YAMAMOTO S et al., Unique palindromic sequences in synthetic oligonucleotides are required to induce and augment INF-mediated natural killer activity, <i>J Immunol</i> , 148(12):4072-4076, Jun. 15, 1992.	

10/743625

FORM PTO-1449/A and B (Modified)		APPLICATION NO.: <span style="background-color: black; color: black;">XXXXXXXXXX</span>	ATTY. DOCKET NO.: C1039/70073US00
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		FILING DATE: Herewith	
		APPLICANT: Krieg et al.	
Sheet 6 of 6		GROUP ART UNIT: <span style="background-color: black; color: black;">1645</span>	EXAMINER: <span style="background-color: black; color: black;">MINNIFIELD</span>

*	YAMAMOTO S, Mode of action of oligonucleotide fraction extracted from <i>Mycobacterium bovis BCG</i> , <i>Kekkaku</i> , 69(9):29-32 (1994).		
*	YAMAMOTO T et al., Ability of oligonucleotides with certain palindromes to induce interferon production and augment natural killer cell activity is associated with their base length, <i>Antisense Res Dev</i> , 4:119-123 (1994).		
*	YAMAMOTO T et al., Lipofection of synthetic oligodeoxyribonucleotide having a palindromic sequence AACGTT to murine splenocytes enhances interferon production and natural killer activity, <i>Microbiol Immunol</i> , 38(10):831-836 (1994).		
*	YAMAMOTO T et al., Synthetic oligonucleotides with certain palindromes stimulate interferon production of human peripheral blood lymphocytes in vitro, <i>Jpn J Cancer Res</i> , 85:775-779 (1994).		
*	YI AK et al., IFN-γ promotes IL-6 and IgM secretion in response to CpG motifs in bacterial DNA and oligonucleotides, <i>J Immunol</i> , 156:558-564 (1996).		
*	YI AK et al., Rapid immune activation by CpG motifs in bacterial DNA, <i>J Immunol</i> , 157:5394-5402 (1996).		
*	ZHAO Q et al., Comparison of cellular binding and uptake of antisense phosphodiester, phosphorothioate, and mixed phosphorothioate and methylphosphonate oligonucleotides. <i>Antisense Res Dev</i> 3(1):53-66, Spring 1993.		
*	ZHAO Q et al., Stage-specific oligonucleotide uptake in murine bone marrow B-cell precursors. <i>Blood</i> 84(11):3660-6, Dec. 1, 1994.		

EXAMINER	DATE CONSIDERED
----------	-----------------

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

\*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. 09/818,918, filed on October 30, 1996 and now issued as U.S. Patent No. 6,207,646, issued on March 27, 2001, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

\*\*a copy of this reference is not provided due in fact to the USPTO rule change effective June 30, 2003

[NOTE - Must provide a copy of any patent, publication, other information listed, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application.]

FORM PTO/1449/A and B (Modified)		APPLICATION NO.: 10/743,625	ATTY. DOCKET NO.: C1039.70073US00
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		FILING DATE: December 22, 2003	CONFIRMATION NO.: Not yet assigned
		APPLICANT: Arthur M. Krieg, et al.	
Sheet	1 of 4	GROUP ART UNIT: 1645	EXAMINER: MINNIEFIELD

*APR 10 2004 10:00 AM*  
PATENT & TRADEMARK OFFICE

### U.S. DOCUMENTS

Examiner's Initials†	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM/DD/YYYY
		Number	Kind Code		
MM	**	5,679,647		Carson et al.	10/21/1997
MM	**	5,994,315		Nyce et al.	11/30/1999
MM	**	6,025,339		Nyce	02/15/2000
MM	**	6,040,296		Nyce	03/21/2000
MM	**	6,174,872	B1	Carson et al.	01/16/2001
MM	**	6,406,705	B1	Davis et al.	06/18/2002
MM	**	6,426,336	B1	Carson et al.	07/30/2002
MM	**	6,429,199	B1	Krieg et al.	08/06/2002
MM	**	6,498,148	B1	Raz	12/24/2002
MM	**	6,514,948	B1	Raz, et al.	02/04/2003
MM	**	6,534,062	B2	Krieg, et al.	03/18/2003
MM	**	6,552,006	B2	Raz et al.	04/22/2003
MM	**	6,562,798	B1	Schwartz	05/13/2003
MM	**	6,589,940	B1	Raz et al.	07/08/2003
MM	**	6,610,661	B1	Carson et al.	08/26/2003
MM	**	6,653,292	B1	Krieg et al.	11/25/2003
MM	**	US 2002/0055477	A1	Van Nest et al	05/09/2002
MM	**	US 2002/0098199	A1	Van Nest et al.	07/25/2002
MM	**	US 2002/0107212	A1	Van Nest et al.	08/08/2002
MM	**	US 2002/0142978	A1	Raz et al.	10/03/2002
MM	**	US 2002/0156033	A1	Bratzler et al.	10/24/2002
MM	**	US 2003/0049266	A1	Fearon et al.	03/13/2003
MM	**	US 2003/0050263	A1	Krieg et al.	03/13/2003
MM	**	US 2003/0078223	A1	Raz et al.	04/24/2003
MM	**	US 2003/0092663	A1	Raz	05/15/2003
MM	**	US 2003/0109469	A1	Carson et al	06/12/2003
MM	**	US 2003/0119773	A1	Raz et al.	06/26/2003
MM	**	US 2003/0129251	A1	Van Nest et al.	07/10/2003
MM	**	US 2003/0133988	A1	Fearon et al.	07/17/2003
MM	**	US 2003/0143213	A1	Raz et al.	07/37/2003
MM	**	US 2003/0147870	A1	Raz et al.	08/07/2003
MM	**	US 2003/0175731	A1	Fearon et al.	09/18/2003
MM	**	US 2003/0186921	A1	Carson et al.	10/02/2003
MM	**	US 2003/0199466	A1	Fearon et al.	10/23/2003
MM	**	US 2003/0212028	A1	Raz et al.	11/13/2003

*MM Minfield*

6-26-05

FORM PTO/1449/A and B (Modified)  INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/743,625	ATTY. DOCKET NO.: C1039.70073US00	
				FILING DATE: December 22, 2003	CONFIRMATION NO.: Not yet assigned	
				APPLICANT: Arthur M. Krieg, et al.		
				GROUP ART UNIT: 1645	EXAMINER: MINNIFIELD	
Sheet 2 of 4						

**U.S. DOCUMENTS (cont.)**

Examiner's Initials†	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM/DD/YYYY
M	**	US 2003/0216340	A1	Van Nest et al.	11/20/2003
M	**	US 2001/0046967	A1	Van Nest	11/29/2001
M	**	US 2002/0028784	A1	Van Nest	03/07/2002
M	**	US 2002/0042387	A1	Raz et al.	04/11/2002
M	**	US 2002/0086839	A1	Raz et al.	07/04/2002
M	**	US 2002/0098199	A1	Van Nest et al.	07/25/2002
M	**	US 2002/0142978	A1	Raz et al.	10/03/2002
M	**	US 2003/0022852	A1	Van Nest et al.	01/30/2003
M	**	US 2003/0059773	A1	Van Nest et al.	03/27/2003
M	**	US 2003/0064064	A1	Dina	04/03/2003
M	**	US 2003/0125284	A1	Raz et al.	07/03/2003
M	**	US 2003/0130217	A1	Raz et al.	07/10/2003
M	**	US 2003/0176373	A1	Raz et al.	09/18/2003
M	**	US 2003/0176389	A1	Raz et al.	09/18/2003
M	**	US 2003/0203861	A1	Carson et al.	10/30/2003
M	**	US 2003/0232780	A1	Carson et al.	12/18/2003
M	**	US 2004/0006034	A1	Raz et al.	01/18/2004
M	**	US 2004/0009942	A1	Van Nest et al.	01/15/2004
M	**	US 2001/0044416	A1	Davis et al.	11/22/2001
M	**	US 2003/0055014	A1	Bratzler	03/20/2002
M	**	US 2002/0091097	A1	Bratzler et al.	07/11/2002
M	**	US 2002/0156033	A1	Bratzler et al.	10/24/2002
M	**	US 2002/0164341	A1	Davis et al.	11/07/2002
M	**	US 2002/0165178	A1	Schetter et al.	11/07/2002
M	**	US 2002/0198165	A1	Bratzler et al.	12/26/2002
M	**	US 2003/0026801	A1	Weiner et al.	02/06/2003
M	**	US 2003/0050263	A1	Krieg et al.	03/13/2003
M	**	US 2003/0091599	A1	Davis et al.	05/15/2003
M	**	US 2003/0100527	A1	Krieg et al.	05/29/2003
M	**	US 2003/0104523	A1	Lipford et al.	06/05/2003
M	**	US 2003/0139364	A1	Krieg et al.	07/24/2003
M	**	US 2003/0148976	A1	Krieg et al.	08/07/2003
M	**	US 2003/0148316	A1	Lipford et al.	08/07/2003
M	**	US 2003/0166001	A1	Lipford	09/04/2003
M	**	US 2003/0181406	A1	Schetter et al.	09/25/2003
M	**	US 2003/0191079	A1	Krieg et al.	10/09/2003
M	**	US 2003/0225016	A1	Fearon et al.	10/23/2003
M	**	US 2004/0006610	A1	Carson et al.	10/23/2003

N M Manfield 6-26-05

FORM PTO/1449/A and B (Modified)  INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/743,625	ATTY. DOCKET NO.: C1039.70073US00	
				FILING DATE: December 22, 2003	CONFIRMATION NO.: Not yet assigned	
				APPLICANT: Arthur M. Krieg, et al.		
				GROUP ART UNIT: 1645	EXAMINER: MINNIFIELD	
Sheet	3	of	4			

#### FOREIGN PATENT DOCUMENTS

Examiner's Initials†	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM/DD/YYYY	Translation (Y/N)
		Office/Country	Number	Kind Code			
MM	B1	WO	98/16247	A1	The Regents of the University of CA	04/23/1998	
MM	*	WO	98/32462	A1		07/30/1998	
MM	B2	WO	98/55495	A2	Dynavax Technologies Corporation	12/10/1998	
MM	B3	WO	99/11275	A2	The Regents of the University of CA	03/11/1999	
MM	*	WO	99/56755	A1		11/11/1999	
MM	*	WO	99/58118	A2		11/18/1999	
MM	B4	WO	99/62923	A2	Dynavax Technologies Corporation	12/09/1999	
MM	*	WO	00/06588	A1		02/10/2000	
MM	*	WO	00/14217	A3		03/16/2000	
MM	B5	WO	00/20039	A1	The Regents of the University of CA	04/13/2000	
MM	B6	WO	00/62787	A1	The Regents of the University of CA	10/26/2000	
MM	*	WO	00/67023	A1		11/09/2000	
MM	*	WO	01/22990	A2		04/05/2001	
MM	*	WO	02/69369	A2		09/06/2002	
MM	B7	WO	98/37919	A1	University of Iowa Research Foundation	09/03/1998	
MM	B8	WO	98/55609	A1	The Regents of the University of CA	12/10/1998	
MM	B9	WO	00/16804	A1	Dynavax Technologies Corporation	03/30/2000	
MM	B10	WO	01/02007	A1	The Regents of the University of CA	01/11/2001	
MM	B11	WO	01/68116	A2	Dynavax Technologies Corporation	09/20/2001	
MM	B12	WO	01/12223	A2	Dynavax Technologies Corporation	02/22/2001	
MM	B13	WO	99/11275	A2	The Regents of the University of CA	03/11/1999	
MM	B14	WO	96/40162	A1	East Carolina University	12/19/1996	
MM	B15	WO	98/49288	A1	Hybridon, Inc.	11/05/1998	

#### OTHER ART - NON PATENT LITERATURE DOCUMENTS

Examiner's Initials†	Cite No.	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume/issue number(s), publisher, city and/or country where published.	Translation (Y/N)
MM	C1	AGRAWAL et al., Molecular med. Today, 6:72-81, 2000.	
	C2	ANDERSON, G. et al., "TH2 and TH2-like cells in allergy and asthma: pharmacological perspectives," TiPS, 15:324-332, 1994.	
MM	C3	BROIDE, D. et al., "DNA-Based Immunization for Asthma", International Archives of Allergy and Immunology, 1999, Pages 453-456, Vol. 118, S. Karger AG. Basel	
MM	C4	CROFT, M. et al., "Generation of Polarized Antigen-specific CD8 Effector Populations: Reciprocal Action of Interleukin (IL)-4 and IL-12 in Promoting Type 2 versus Type 1 Cytokine Profiles", J. Exp. Med., November 1994, Pages 1715-1728, Vol. 180, The Rockefeller University Press	
MM	C5	HUANG, L.Y. et al., "Induction and Regulation of Th1-Inducing Cytokines by Bacterial DNA, Lipopolysaccharide, and Heat-Inactivated Bacteria", Infection and Immunity, December 1999, Pages 6257-6263, Vol. 67, No. 12, American Society for Microbiology	
	C6	KAWANO, K. et al., "Analysis and regulation of interferon-gamma production by peripheral blood lymphocytes from patients with bronchial asthma," Arerugi, 43:3482-91, 1994 (Abstract).	
MM	C7	KLINE, J.N. et al., "CpG oligodeoxynucleotides do not require T <sub>H</sub> 1 cytokines to prevent eosinophilic airway inflammation in a murine model of asthma", J. Allergy Clin. Immunol., December 1999, Pages 1258-1264, Vol. 104, No. 6	

NM Minnifield 6-26-05

FORM PTO/1449/A and B (Modified)		APPLICATION NO.: 10/743,625	ATTY. DOCKET NO.: C1039.70073US00
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		FILING DATE: December 22, 2003	CONFIRMATION NO.: Not yet assigned
		APPLICANT: Arthur M. Krieg, et al.	
Sheet	4	of	4
		GROUP ART UNIT: <b>1645</b>	EXAMINER: <b>Minnifield</b>

OTHER ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials†	Cite No.	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume/issue number(s), publisher, city and/or country where published.	Translation (Y/N)
<i>MM</i>	C8	KLINMAN, D.M., et al., "Activation of the innate immune system by CpG oligodeoxynucleotides: immunoprotective activity and safety," <i>Springer Semin Immunopathol</i> 22:173-183, 2000	
<i>MM</i>	C9	KRIEG, A.M., "An innate immune defense mechanism based on the recognition of CpG motifs in microbial DNA," <i>J Lab Clin Med</i> 128(2):128/33, 1996 (Abstract).	
<i>MM</i>	C10	KRIEG, A.M., et al., "CpG motifs in bacterial DNA and their immune effect." <i>Annu Rev Immunol</i> 20:709-760, 2002.	
<i>MM</i>	C11	KRIEG et al., <i>Immunology Today</i> 21(10):521-526, 2000.	
<i>MM</i>	C12	KRIEG, A.M. et al., "Immune effects and therapeutic applications of CpG motifs in bacterial DNA", <i>Immunopharmacology</i> , 2000, Pages 303-305, Vol. 48, Elsevier Science B.V.	
<i>MM</i>	C13	LIPFORD, G.B. et al., "Bacterial DNA as immune cell activator", <i>Trends Microbiol.</i> , 1998, Pages 496-500, Vol. 6, No. 12, Elsevier Science	
<i>MM</i>	C14	LIPFORD, G.B. et al., "Immunostimulatory DNA: sequence-dependent production of potentially harmful or useful cytokines," <i>Eur J Immunol</i> 27:3420-3426, 1997.	
<i>MM</i>	C15	MCCLUSKIE et al., <i>Molecular Med</i> 5(5):287-300, 1999.	
<i>MM</i>	C16	RICCI, M. et al., "T cells, cytokines, IgE and allergic airways inflammation," <i>J Invest Allergol Clin Immunol</i> , 4(5):214-220, 1994.	
<i>MM</i>	C17	SPIEGELBERG, H. et al., "Recognition of T Cell Epitopes and Lymphokine Secretion by Rye Grass Allergen Lolium perenne I-specific Human T Cell Clones," <i>J of Immunology</i> , 4706-4711, 1994.	
<i>MM</i>	C18	VAN UDEN, J. et al., "Immunostimulatory DNA and applications to allergic disease", <i>J. Allergy Clin Immunol</i> , November 1999, Pages 902-910, Vol. 104, No. 5	
<i>MM</i>	C19	WALKER, C. et al., "Activated T Cells and cytokines in bronchoalveolar lavages from patients with various lung diseases associated with eosinophilia," <i>Am J Respir Crit Care Med</i> , 150:1038-1048, 1994.	
<i>MM</i>	C20	ZIMMERMANN, S. et al., "CpG oligodeoxynucleotides trigger protective and curative Th1 responses in lethal murine leishmaniasis," <i>J Immunol</i> 160:3627/3630, 1998.	

EXAMINER	<i>MM Minnifield</i>	DATE CONSIDERED	<i>6-26-05</i>
----------	----------------------	-----------------	----------------

†EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

\*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. 09/818,918 or Serial No. 08/738,652, filed on October 30, 1996 and now issued as U.S. Patent No. 6,207,646, issued on March 27, 2001, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation/in/part, and divisional applications).

\*\* copies of these patents and patent applications are not enclosed pursuant to the waiver by the USPTO of the requirement under 37 C.F.R. 1.98 (a)(2)(i) for patent applications filed after June 30, 2003.